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Akt1 is a well-characterized mediator of muscle hypertrophy. In this issue of Cell Metabolism, Izumiya et al.
(2008) reveal a striking link between Akt1 signaling, fast muscle fiber size, and whole-body metabolism.
These results provide new insights into the ability of muscle to combat diet-induced obesity and metabolic
dysfunction.As is becoming increasingly common in
many countries, the United States is fac-
ing an epidemic of obesity. Given that
obesity represents the single most com-
mon underlying cause of increased
morbidity and mortality due to either met-
abolic dysfunction or cardiovascular dis-
ease, the health care costs associated
with this issue are enormous. In fact, the
term ‘‘metabolic syndrome’’ has been
given to this clustering of risk factors (cen-
tral obesity, dyslipidemia, and insulin re-
sistance), and this diagnosis can now be
applied to roughly a quarter of the US
population over the age of 20 and almost
half of the population over age 45 (Reilly
and Rader, 2003). While current pharma-
ceutical interventions are moderately ef-
fective in treating the clinical symptoms
of metabolic syndrome, at this point only
rigorous diet and lifestyle modifications
(such as endurance exercise) are thought
to be capable of significantly preventing
harmful increases in fat mass that will ulti-
mately shorten life span. Now, a new
report by Izumiya et al. (2008) elegantly
demonstrates that fast type IIb muscle
fiber hypertrophy in response to Akt1
signaling blocks metabolic dysregulation
and weight gain due to a high-fat/high-
sugar diet, indicating that increasing fast
muscle size via strength training may
also be an important intervention for
at-risk populations.
Skeletal muscle fibers can be classified
by their morphological, contractile, and
metabolic characteristics into one of two
broad categories: slow (type I) fibers ex-
hibit relatively low contractile velocities
and are rich in mitochondria and the en-
zymes of oxidative energy metabolism,
while at the other end of the spectrum
(type I4 IIa4 IId/x4 IIb), fast type IIb
fibers contract more rapidly and are pre-
disposed toward glycolytic metabolism.In humans, slow muscle fiber percentage
and skeletal muscle glucose transport
are reduced in obese and diabetic popu-
lations, and regular endurance-type exer-
cise can positively impact whole-body
metabolism primarily though increased
prevalence of, and adaptation to, the
slow skeletal muscle fiber populations
(Daugaard and Richter, 2001; Hickey
et al., 1995). In animal models, altering
either the number or function of slowmus-
cle fibers has been shown to directly
impact fat mass and the development of
obesity due to dietary modification. The
phosphatase calcineurin promotes slow
muscle fiber gene expression, and trans-
genic mice expressing a constitutively
active form of calcineurin (CnA*) demon-
strate increased glucose uptake along
with increasedexpression of the insulin re-
ceptor and glucose transporter 4 (GLUT4)
(Naya et al., 2000; Ryder et al., 2003).
Similarly, skeletalmuscle-specific overex-
pression of constitutively active PPARd
increases slow muscle fiber prevalence
and confers resistance to the develop-
ment of diet-induced obesity (Wang et al.,
2004).
While these studies highlight the impor-
tance of slow skeletal muscle fibers in
modulating whole-body metabolism, the
ability of the fast muscle fiber populations
to affect blood glucose homeostasis, in-
sulin sensitivity, and the development of
obesity is less well understood. Endur-
ance training promotes slow muscle fiber
adaptation, while fast muscle fibers are
more responsive to resistance training
paradigms. In humans, such training has
been linked to reduced adiposity and
improved insulin sensitivity and is now
a recommended mode of exercise for
individuals with type 2 diabetes (Albright
et al., 2000; Schmitz et al., 2007). In
mice, however, little has been done toCell Metabolisdirectly assess the ability of fast muscle
size/function to affect diet-induced obe-
sity and associated metabolic dysregula-
tion.
Izumiya et al. (2008) have addressed
this question by using Akt1 to stimulate
type IIb muscle fiber hypertrophy. The
serine/threonine kinase Akt1 (also known
as protein kinase B [PKB]) plays a central
role in numerous, diverse biological pro-
cesses and is well known for its ability
to promote skeletal muscle fiber hyper-
trophy via increased protein synthesis.
Once activated by phosphatidylinositol
3-kinase (PI3K), Akt1 modulates the
activity of several key regulators of pro-
tein synthesis, translation, and degra-
dation including the mammalian target
of rapamycin (mTOR), 4EBP-1, glycogen
synthase kinase (GSK-3b), and the FoxO
family of transcription factors (Frost and
Lang, 2007) (see Figure 1). Not surpris-
ingly, constitutive activation of Akt1 in
skeletalmuscle in vivo results in significant
muscle fiber hypertrophy and increased
glucose uptake in vitro (Hajduch et al.,
1998; Lai et al., 2004).
Here, Izumiya et al. show that targeted
expression of constitutively active Akt1
(myrAkt1*) to fast type IIb muscle fibers
results in significantmuscle fiber hypertro-
phy, increased muscle mass, increased
strength, and reduced running capacity.
To investigate the ability of this hypertro-
phy to impact diet-induced obesity and
metabolic dysfunction, Izumiya et al. ex-
posed both control and transgenic mice
to a high-fat/high-sucrose (HF/HS) diet. In
this context, activation of Akt1 triggered a
striking reduction of body mass due to
decreased visceral fat mass and white
adipocyte atrophy. These effects of en-
hanced Akt1 signaling on diet-induced
obesity were directly related to muscle
hypertrophy—blocking hypertrophy withm 7, February 2008 ª2008 Elsevier Inc. 97
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fects of transgene induction on body and
fat mass.
As mentioned above, hallmarks of the
metabolic syndrome include elevated
levels of blood glucose, insulin, and leptin.
This compromised metabolic state was
induced by the HF/HS diet in control ani-
mals, but not in the Akt1 transgenic
mice. While glucose uptake was 2-fold
higher in transgenic gastrocnemius as
compared to control gastrocnemius, glu-
cose uptake tended to be lower in non-
transgenic tissues such as heart, white
adipose tissue, liver, and slow skeletal
muscle (soleus). Analysis of skeletal
muscle gene expression with and without
Akt1 transgene induction revealed signifi-
cant increases in transcripts for the key
glycolytic genes hexokinase, phospho-
fructokinase, and lactate dehydrogenase
A combined with significant decreases
in transcripts for the oxidative genes
PGC-1a, PPARa, and PPARd.
Interestingly, Akt1 transgenic mice
demonstrated enhanced oxygen con-
sumption coupled with reduced physical
activity levels and a lowered respiratory98 Cell Metabolism 7, February 2008 ª2008 Eexchange ratio, indicating a greater reli-
ance on fatty acid oxidation for metabolic
energy requirements. As predicted, expo-
sure to the HF/HS diet hadwidespread ef-
fects on liver gene expression, with >1200
genes significantly altered by diet. Re-
markably, Akt1-mediated fast skeletal
muscle hypertrophy reversed 67% (861
of 1281 genes) of these diet-induced
changes in liver gene expression. Nota-
bly, Akt1 transgene induction increased
levels of genes involved in both gluconeo-
genesis and fatty acid metabolism in the
liver and resulted in enhanced fatty acid
oxidation in isolated liver samples.
These findings raise several intriguing
questions for future research. Given that
this study focused on type IIb fiber hy-
pertrophy in selected skeletal muscles,
would the same effects be observed for
other fast fiber types (IIa or IId/x) or other
muscles? What is the smallest degree of
hypertrophy that would confer these pro-
tective effects? As the authors comment,
how does Akt1-induced muscle hypertro-
phy alter the expression of specific circu-
lating factors (i.e., myokines) that may
have systemic effects on substratelsevier Inc.uptake and utilization? Given that males
typically show greater hypertrophy in re-
sponse to resistance exercise and lose
more weight in response to exercise
than females do, are there gender-spe-
cific differences in the ability of skeletal
muscle size and/or function to modulate
whole-body metabolism?
In summary, the work of Izumiya et al.
(2008) reveals the intricate interplay
between diet, energy balance, and the
function/morphology of diverse tissue
systems such as skeletal muscle and
liver. These findings indicate that inter-
ventions designed to increase skeletal
muscle mass in at-risk human popula-
tions may prove to be critical weapons in
the fight against obesity and obesity-
related comorbidities including diabetes,
heart disease, stroke, hypertension, and
cancer.
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e294.Figure 1. Akt1-Mediated Skeletal Muscle Growth Alters Whole-Body Metabolism and
Prevents Diet-Induced Obesity and Metabolic Dysfunction
Induction of the Akt1 signaling pathway in fast skeletal muscle results in type IIb fiber hypertrophy and
increased muscle mass via activation of the mammalian target of rapamycin (mTOR) and subsequent
downstream regulatory molecules. When subjected to a high-fat/high-sucrose diet, Akt1 transgenic
mice exhibit reduced fat mass, increased muscle glucose uptake, and reductions in plasma glucose,
insulin, and leptin levels. In non-transgene-expressing tissues such as the liver and heart, fat uptake
and oxidation are enhanced.
